Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 1, 2011Journal of Blood MedicineOpen Access

Treatment of patients with von Willebrand disease

View Full Paper
Ask AI
Bookmark
Share

Population

Patients with von Willebrand disease (vWD)

Design

Review

Authors

RARaza AlikhanCardiff and Vale University Health Board

Discussion

Loading...

Member takes

Overview

Affirms desmopressin preference for type 1 vWD; leaves open need for prospective trials on concentrate selection in non-responders.

Structured PICO

P
Population
Patients with von Willebrand disease (vWD)
I
Intervention
Desmopressin (DDAVP), vWF:FVIII concentrates, and antifibrinolytic treatment

Desmopressin is the treatment of choice for type 1 vWD, while vWF:FVIII concentrates are used when DDAVP is ineffective or contraindicated.

Cite This Study

Raza Alikhan (2011) studied this question.

synapsesocial.com/papers/6a7105ebabc331a85807a2e8https://doi.org/10.2147/jbm.s9890
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Diagnosis and management of von Willebrand disease1999 · 31 citations
  2. 2Targeting von Willebrand disease: the current status and future directions of management therapies2023 · 2 citations
  3. 3Von <scp>W</scp>illebrand disease – the ‘<scp>D</scp>os’ and ‘<scp>D</scp>on'ts’ in surgery2016 · 37 citations
  4. 4Treatment of von Willebrand Disease2016 · 66 citations
  5. 5Current Therapeutic Innovations in the Treatment of Von Willebrand Disease2025